Immune-modified ex vivo platform can measure treatment response of ovarian cancer
KIYATEC, Inc researchers demonstrated that their immune-modified ex vivo platform can measure treatment response through direct interaction between a patient's cancer and infiltrating immune cells, and immuno-oncology agents.
More... |
All times are GMT -7. The time now is 11:13 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021